Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹36,689 Cr
P/E Ratio
50.3
P/B Ratio
5.26
Industry P/E
37.87
Debt to Equity
0.22
ROE
8.7 %
ROCE
13.1 %
Div. Yield
0.28 %
Book Value
275.03
EPS
32.94
CFO
₹6,567.95 Cr
EBITDA
₹8,120.07 Cr
Net Profit
₹4,916.02 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| -14.72 | 2.75 | -8.71 | 9.20 | 12.06 | 13.52 | 15.86 |
|
BSE Healthcare
| -4.95 | 1.92 | -0.50 | 24.13 | 20.27 | 23.08 | 9.93 |
|
BSE Mid Cap
| -6.03 | 4.20 | 0.42 | 7.41 | 20.85 | 30.15 | 15.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| 51.45 | 32.03 | -22.18 | -0.61 | 92.28 | 39.19 | 33.73 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2,790.40 | 34,801.14 | 38.76 | 24.79 | |
| 5,201.20 | 62,409.34 | 28.98 | 19.84 | |
| 326.75 | 39,187.58 | 48.72 | 3.88 | |
| 2,916.00 | 49,411.50 | 57.51 | 49.5 |
2 min read•By Value Research
Which stocks are vulnerable to Brexit?
4 min read•By Kumar Shankar Roy
5 min read•By Vikas Vardhan
3 min read•By Research Desk
5 min read•By Value Research
3 min read•By Research Desk
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of... anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. Read more
Incorporated
1949
Chairman
Premchand Godha
Managing Director
Pranay Godha
Group
Ipca Laboratories
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Ipca Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsSlump Sale Of Manufacturing Unit And Acquisition
28-Mar-2025Standalone And Consolidated Q3FY25 Results
13-Feb-2025
The total asset value of Ipca Laboratories Ltd stood at ₹ 11,424 Cr as on 31-Dec-24
The share price of Ipca Laboratories Ltd is ₹1,445.70 (NSE) and ₹1,446.15 (BSE) as of 24-Apr-2025 IST. Ipca Laboratories Ltd has given a return of 12.06% in the last 3 years.
Ipca Laboratories Ltd has a market capitalisation of ₹ 36,689 Cr as on 24-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Ipca Laboratories Ltd is 5.26 times as on 24-Apr-2025, a 0% premium to its peers’ median range of 5.26 times.
The P/E ratio of Ipca Laboratories Ltd is 50.30 times as on 24-Apr-2025, a 33% premium to its peers’ median range of 37.87 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ipca Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Ipca Laboratories Ltd.
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
The promoters of Ipca Laboratories Ltd are Kaygee Investments Private Limited and Kaygee Laboratories Private Limited. They collectively own 28.08 per cent of the total equity. The chairman of the company is Premchand Godha
There is no promoter pledging in Ipca Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
59,194
|
|
|
49,284
|
|
|
39,764
|
|
|
33,665
|
| Ipca Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.83
|
|
Operating margin(%)
|
14.02
|
|
Net Margin(%)
|
8.22
|
|
Dividend yield(%)
|
0.28
|
Yes, TTM profit after tax of Ipca Laboratories Ltd was ₹729 Cr.
₹-25.20
(
